PSTX — Poseida Therapeutics Share News
0.000.00%
Last trade - 00:00- $927.88m
- $755.94m
- $64.70m
Poseida Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Poseida Therapeutics Q4 Revenue $31.2 Million
Poseida Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Poseida Therapeutics To Present Interim Results From Phase 1 Trial Of P-Psma-101 At Asco Genitourinary Cancers Symposium
Brief: Poseida Therapeutics Announces Eric Ostertag To Transition Role Of CEO To Current President Mark Gergen
Brief: Poseida Therapeutics Announces FDA Clearance Of Investigational New Drug Application For P-MUC1C-ALLO1
Brief: Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting
Poseida Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Poseida Therapeutics Posts Quarterly Loss Per Share Of $0.68
Brief: Poseida Therapeutics To Present Preclinical Data Of Fully Allogeneic CAR-T Product Candidates
Poseida Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: Poseida Therapeutics Inc Announces Leadership Appointments
Poseida rises on gene therapy development deal with Takeda
Brief: Poseida Therapeutics Announces Research Collaboration With Takeda For Novel Non-Viral In Vivo Gene Therapies
Poseida Therapeutics slumps despite promising data from prostate cancer study
Brief: Poseida Therapeutics Gets FDA Clearance For Trial Of Myeloma Treatment
Brief: Poseida Therapeutics, Inc. Files For Mixed Shelf Of Up To $300 Million – SEC Filing
Brief: Poseida Therapeutics Reports Program Updates And Q2 Financial Results
Poseida Therapeutics Inc reports results for the quarter ended in June - Earnings Summary